Zai Lab (ZLAB) said Monday that China's National Medical Products Administration accepted its supplemental New Drug Application for its experimental therapy, repotrectinib, to treat adult patients with certain advanced or metastatic solid tumors.
The company said the application targets patients whose cancer is either too advanced for surgery without serious complications or who have no effective treatment options left after prior therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.